Free Trial
NASDAQ:NAUT

Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

Nautilus Biotechnology logo
$0.76 +0.00 (+0.57%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.76 +0.00 (+0.09%)
As of 08/1/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Nautilus Biotechnology Stock (NASDAQ:NAUT)

Key Stats

Today's Range
$0.74
$0.79
50-Day Range
$0.69
$0.82
52-Week Range
$0.66
$3.09
Volume
139,938 shs
Average Volume
156,050 shs
Market Capitalization
$96.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.13
Consensus Rating
Sell

Company Overview

Nautilus Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

NAUT MarketRank™: 

Nautilus Biotechnology scored higher than 66% of companies evaluated by MarketBeat, and ranked 310th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nautilus Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Nautilus Biotechnology has received no research coverage in the past 90 days.

  • Read more about Nautilus Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.57) to ($0.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nautilus Biotechnology is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nautilus Biotechnology is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nautilus Biotechnology has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.41% of the float of Nautilus Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Nautilus Biotechnology has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nautilus Biotechnology has recently decreased by 18.92%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Nautilus Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Nautilus Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.41% of the float of Nautilus Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Nautilus Biotechnology has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nautilus Biotechnology has recently decreased by 18.92%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Nautilus Biotechnology has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Nautilus Biotechnology this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for NAUT on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nautilus Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $21,405.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    41.10% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nautilus Biotechnology's insider trading history.
Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

NAUT Stock News Headlines

Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.
See More Headlines

NAUT Stock Analysis - Frequently Asked Questions

Nautilus Biotechnology's stock was trading at $1.68 at the beginning of 2025. Since then, NAUT stock has decreased by 54.5% and is now trading at $0.7643.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) posted its earnings results on Thursday, July, 31st. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02.
Read the conference call transcript
.

Nautilus Biotechnology's top institutional investors include Clarius Group LLC (0.84%), Y Intercept Hong Kong Ltd (0.18%), Callan Family Office LLC (0.04%) and Presidio Capital Management LLC (0.03%). Insiders that own company stock include Parag Mallick, Sujal M Patel, Subramanian Sankar, Anna Mowry, Matthew B Murphy, Gwen E Weld and Mary E Godwin.
View institutional ownership trends
.

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nautilus Biotechnology investors own include JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Home Depot (HD) and Visa (V).

Company Calendar

Last Earnings
7/31/2025
Today
8/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:NAUT
CIK
1808805
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

High Price Target
$2.50
Low Price Target
$1.75
Potential Upside/Downside
+178.0%
Consensus Rating
Sell
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.52)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$70.78 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-31.45%
Return on Assets
-26.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
17.36
Quick Ratio
17.36

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.66 per share
Price / Book
0.46

Miscellaneous

Outstanding Shares
126,150,000
Free Float
74,301,000
Market Cap
$96.42 million
Optionable
Optionable
Beta
1.42
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:NAUT) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners